Tata Motors is seeking an image makeover with the curvaceous hatchback, Zica.
The government plans to inject a total Rs 70,000 crore into the lenders over four years
Home loans also pose lower bad-debt risks for the banks than corporate loans.
ICICI Bank has the largest proportion of SDR loans as a percentage of its total, followed by state-run United Bank of India and Canara Bank.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
The changes would be the most ambitious overhaul to date of rules governing the liquidation or revival of companies in India.
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
Coffee Day Enterprises Ltd is backed by KKR & Co.
Across India, decades of mismanagement and political meddling have left utilities selling electricity below cost and turning a blind eye to rampant theft.
India rejects patent on Pfizer's arthritis drug
Cipla has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million.
At the current market price of the stock, that stake would be valued at about $1.5 billion.
A total of 41 companies had applied for the permit
The spike at private sector lenders like ICICI Bank and Axis Bank follows a push to grab market share from India's dominant state banks.
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
The government plans to transfer all subsidies including food, fertiliser and kerosene, potentially taking direct payments to more than $60 billion.
Drugs under exemption make up roughly 95 per cent of the antiretrovirals used by India's AIDS patients
Bad debt rules are steps in right direction.
State Bank of India expects decent growth in FY16.
Despite Indian economy recovering, there is very little room for loan growth, say bankers.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances